BOVILIS® NASALGEN® 3
Bovine Rhinotracheitis-Parainfluenza 3-Respiratory Syncytial Virus Vaccine
Product Description
The color of longer IBR protection.
BOVILIS® NASALGEN® 3 offers young calves an unrivaled BRD defense. With 195 days of IBR protection plus BRSV and PI3, BOVILIS NASALGEN 3 is the insurance you need to give your young calves the strong foundation they deserve. And with a unique BluShadow®, there’s no second guessing which animals have been vaccinated.
Indications
This product has been shown to be effective for the vaccination of healthy cattle, 1 week of age or older against infectious bovine rhinotracheitis (IBR) virus, bovine respiratory syncytial virus (BRSV) and parainfluenza 3 virus (PI3). Duration of immunity against IBR is at least 195 days, against BRSV is at least 78 days, and against PI3 is at least 95 days.
Diseases
- Infectious bovine rhinotracheitis (IBR)
- Bovine respiratory syncytial virus (BRSV)
- Parainfluenze 3 (PI3)
Designed for no injection site reactions to help your operation meet Beef Quality Assurance standards.
Key Benefits
- Designed with an IBR that is not temperature-sensitive, ensuring the vaccine will replicate and protect in any situation.1
- Unique BluShadow® for confident administration.
- Proven safe in pregnant cows and in calves nursing pregnant cows.
Long-lasting Duration of Immunity
- 195 days against IBR
- 95 days against PI3
- 78 days against BRSV
A Game-changing Vaccine
Innovation is critical in vaccine development. For decades it was believed that vaccinating young animals was not effective because of maternal antibody interference. The industry needed to find a way to protect young calves from BRD.
Learn from members of the team who brought to market BOVILIS NASALGEN 3-PMH — the first and only intranasal BRD vaccine offering protection against viral and bacterial pathogens.
Dosage
Shake well and administer a 2 mL dose by the intranasal route. For advice on revaccination frequency, contact your veterinarian.
Supplied
20 mL x 10 doses (2 mL per dose)
25 mL x 1 dose/2 mL x 25 doses (2mL per dose)
100 mL x 50 doses (2 mL per dose)
Caution
Store at 2 to 8°C (35 to 46°F). Fetal health risks associated with the vaccination of pregnant animals with this vaccine cannot be unequivocally determined during clinical trials conducted for licensure. Appropriate strategies to address the risks associated with vaccine use in pregnant animals should be discussed with a veterinarian. Use entire contents when first opened. Do not use chemical disinfectants to sterilize syringes or needles. Do not mix with other products, except as specified on the label. Inactivate unused contents before disposal. Do not vaccinate within 21 days of slaughter. Anaphylactoid reactions may occur following use. Antidote: Epinephrine. Contains Penicillin and Streptomycin as a preservative. In case of human exposure, contact a physician.
FOR ANIMAL USE ONLY.
Research
Duration of Immunity of the Parainfluenza 3 Fraction
Results of this study demonstrate the duration of immunity of the PI3 fraction of BOVILIS NASALGEN 3.
Duration of Immunity of the Bovine Respiratory Syncytial Virus Fraction
Results of this study demonstrate the duration of immunity of the BRSV fraction of BOVILS NASALGEN 3.
Duration of Immunity of the Infectious Bovine Rhinotracheitis Virus Fraction
Results of this study demonstrate the duration of immunity of the IBR fraction of BOVILIS® NASALGEN 3®.
Efficacy of the Bovine Parainfluenza 3 Virus Fraction
Results of this study demonstrate protective efficacy of the PI3 fraction of BOVILIS NASALGEN 3.
Efficacy of the Bovine Respiratory Syncytial Virus Fraction
Results of this study demonstrate the protective efficacy for the BRSV fraction of BOVILIS NASALGEN 3.
Efficacy of the Infectious Bovine Rhinotracheitis Virus Fraction
Results of this study demonstrate protective efficacy for the IBR fraction of BOVILIS NASALGEN 3.
No items to show.
Contact
U.S. only: Merck Animal Health livestocktechsrvc@merck-animal-health.com or call 1-800-211-3573
For more information regarding efficacy and safety data, go to productdata.aphis.usda.gov
For additional information, please see the product label.
References
1. Grissett GP, et al. Effect of Ambient Temperature on Viral Replication and Serum Antibody Titers Following Administration of a Commercial Intranasal Modified-Live Infectious Bovine Rhinotracheitis-Parainfluenza-3 Virus Vaccine to Beef Cattle Housed in High- and Moderate-Ambient Temperature Environments. Am J Vet Res. 2014;75(12):1076-1082.
The dry period is an important time to minimize mastitis risk and vaccinate cows to protect their calves from scours. Give your dry cows the complete care they deserve.
Sign up to receive cattle health management insights, industry news and more sent straight to your inbox.